Replicor is a clinical-stage company developing novel NUCLEIC ACID-BASED POLYMERS (NAPs): oligonucleotides whose antiviral activity is strictly dependent on the polymer chemistry of oligonucleotides which can be preserved independently of the sequence of nucleotides present. NAPs have a very important safety advantage over all other existing oligonucleotide-based drugs such as aptamers, antisense oligonucleotides and siRNA: because NAP’s activity is not sequence dependent, NAPs can be engineered with sequences which retain antiviral activity but which do not have pro-inflammatory activity or off target effects common with other oligonucleotide-based drugs, rendering them safe and well tolerated.
Replicor has focused its efforts on developing a cure for HBV and HDV. Three POC Phase II clinical trials have demonstrated that NAP therapy (including REP 2139 with immunotherapy (Pegasys® or Zadaxin®)) is well tolerated and results in antiviral responses that include:
Continuing updates of Replicor clinical trials in progress will be presented at all major liver conferences in 2017. Replicor’s latest clinical data can be viewed here.
Replicor’s presentations at the 2016 AASLD annual meeting can be reviewed here